# US 8,604,087 B2 · Composition for treating or preventing amyloid-related diseases comprising 4-O-methylhonokiol

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,604,087 B2
- Document ID: US8604087B2
- Status: Granted
- Kind: B2
- Application number: 13/120,818
- Filed: 2009-09-25
- Published: 2011-08-25
- Granted: 2013-12-10
- Earliest claimed: 2008-09-25
- Assignees: Bioland
- Applicants: Ki Ho Kim; Ki Soo Kim; Young Heui Kim; Jin Guk Kim; Kyoung Tae Kim; Chang Sung Han; Sang iL Lee
- Inventors: Ki Ho Kim; Ki Soo Kim; Young Heui Kim; Jin Guk Kim; Kyoung Tae Kim; Chang Sung Han; Sang iL Lee
- Web page: https://patentgrep.com/patent/US8604087B2

## CPC

- A61K 31/085: having an ether linkage to aromatic ring nuclear carbon
- A23L 2/52: Adding ingredients (adding preservatives A23B70/10)
- A23L 33/105: Plant extracts, their artificial duplicates or their derivatives
- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 36/575: Magnolia
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed is a composition for treating or preventing amyloid-related diseases including 4-O-methylhonokiol as an active ingredient. More specifically, a pharmaceutical composition including 4-O-methylhonokiol, which is effective for treating or preventing amyloid-related diseases such as Alzheimer's disease, cognitive disorder, defective memory, amyloidosis, etc. is disclosed. The inventors of the present disclosure have found out for the first time that 4-O-methylhonokiol inhibits the production of β-amyloid. It has been confirmed to be useful in treating or preventing amyloid-related diseases. Through animal tests including water maze test and passive avoidance test on mice, 4-O-methylhonokiol has been confirmed to be effective for amyloid-related diseases such as Alzheimer's disease, defective memory, cognitive disorder, and the like. It was further confirmed through acetylcholinesterase activity inhibition test using mouse brain cortex and hippocampus tissue that they are particularly effective in treating or preventing Alzheimer's disease among the amyloid-related diseases.

## Claims

### Claim 1

A method for reducing beta-amyloid comprising administering a pharmaceutically effective dosage of 4-O-methylhonokiol or a pharmaceutically acceptable salt thereof to a subject in need thereof.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the pharmaceutically acceptable salt is a metal salt with lithium, sodium, potassium, calcium or magnesium bound to the hydroxyl group of the 4-O-methylhonokiol.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the 4-O-methylhonokiol is isolated from Magnolia officinalis Rehd. et Wils. extract.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the 4-O-methylhonokiol is chemically synthesized from methylation of honokiol.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the subject has a beta-amyloid-related disease selected from a group consisting of Alzheimer's disease, cognitive disorder, defective memory and amyloidosis.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the 4-O-methylhonokiol or a pharmaceutically acceptable salt thereof is administered as a composition comprising the 4-O-methylhonokiol or the pharmaceutically acceptable salt thereof in an amount of 0.0001-90 wt % based on the total weight.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the composition is a pharmaceutical or functional food composition.

### Claim 8 (depends on 6)

The method according to claim 6, wherein the composition is in the form of powder, granule, tablet, capsule, injection, cream, gel, patch, spray or ointment.